The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2020-11, Vol.83 (5), p.1523-1526
Main Authors: Syed, Maha N., Shin, Daniel B., Wan, Marilyn T., Winthrop, Kevin L., Gelfand, Joel M.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Betacoronavirus - immunology
Biological Products - administration & dosage
Biological Products - adverse effects
Clinical Decision-Making
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Coronavirus Infections - epidemiology
Coronavirus Infections - immunology
Coronavirus Infections - prevention & control
Coronavirus Infections - transmission
COVID-19
Humans
Interleukin-23 Subunit p19 - antagonists & inhibitors
Interleukin-23 Subunit p19 - metabolism
Odds Ratio
Pandemics - prevention & control
Pneumonia, Viral - epidemiology
Pneumonia, Viral - immunology
Pneumonia, Viral - prevention & control
Pneumonia, Viral - transmission
Psoriasis - drug therapy
Psoriasis - immunology
Research Letter
Respiratory Tract Infections - chemically induced
Respiratory Tract Infections - epidemiology
Respiratory Tract Infections - immunology
Respiratory Tract Infections - prevention & control
Risk Assessment
SARS-CoV-2
Signal Transduction - drug effects
Signal Transduction - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2020.06.1014